ERBB2 and breast cancer: The CDK4/6 inhibitors combined with ET is the standard of care for post-menopausal ER-positive/HER2 negative BC, and in combination with an LHRH agonist for pre-menopausal women, reporting an improvement in PFS, but a limited efficacy in BM control [94,95].